Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Inclusion Criteria: * histological confirmed diagnosis cancer * symptomatic malignant ascites * EpCAM positive tumor * EOCG 0-2 * negative pregnancy Exclusion Criteria: * acute or chronic infection * exposure to investigational product, cancer chemo- or radiotherapy within the last 28 days * previous treatment with mouse monoclonal antibodies * known or suspected hypersensitivity to Removab or similar antibodies * inadequate renal function * inadequate hepatic function (AST, ALt, GTP,\< x ULN; bilirubin \<1.5xULN) * Platelets \> 80000 cells/mm3; absolute neutrophil count (ANC) \< 1500 cells/mm3 * BMI \< 17 * Patients with reduced nutritional status * Ileus within the last 30 days * Brain metastases in cancer history * Pregnant and nursing women * history of myocardial infarction, congestive heart failure or relevant cardiac arrhythmia within previous 3 months * inadequate respiratory function in option of investigator